ACM
TPST icon

Altium Capital Management’s Tempest Therapeutics TPST Stock Holding History

Altium Capital Management’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-41,923
Closed -$763K – 93
2024
Q3 		$763K Buy
+41,923
New +$859K 0.22% 50

Other funds holding TPST

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Altium Capital Management's TPST Position: Q4 2024 in Review

Altium Capital Management sold out of Tempest Therapeutics (TPST) in Q4 2024, closing a stake of 41,923 shares — an estimated $763K sold.

Altium Capital Management first reported a position in TPST in Q3 2024 and held it in 1 quarter. The position peaked at $763K in Q3 2024. 33 funds tracked by Wall St. Rank hold TPST as of Q4 2024.

  • Altium Capital Management reported no remaining Tempest Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Altium Capital Management sold 41,923 Tempest Therapeutics shares in Q4 2024, an estimated $763K.
  • Altium Capital Management first reported a position in Tempest Therapeutics in Q3 2024 and held it in 1 quarter.
  • Altium Capital Management's Tempest Therapeutics position peaked at $763K in Q3 2024.
  • 33 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q4 2024.

Based on Altium Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.